What is Strata Critical Medical Inc's earnings per share (EPS)?

Strata Critical Medical Inc (SRTAW) reported diluted earnings per share of $0.50 for fiscal year 2025. This represents a 242.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Strata Critical Medical Inc Financials

SRTAW

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Strata Critical Medical Inc (SRTAW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 56/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Strata Critical Medical Inc has an operating margin of -11.3%, meaning the company retains $-11 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -15.3% the prior year.

Growth

Strata Critical Medical Inc's revenue surged 34.3% year-over-year to $197.1M, reflecting rapid business expansion. This strong growth earns a score of 90/100.

Leverage

Strata Critical Medical Inc carries a low D/E ratio of 0.17, meaning only $0.17 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 6.38, Strata Critical Medical Inc holds $6.38 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While Strata Critical Medical Inc generated -$48.9M in operating cash flow, capex of $9.6M consumed most of it, leaving -$58.5M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Strata Critical Medical Inc's ROE of 14.8% shows moderate profitability relative to equity, earning a score of 44/100. This is up from -12.3% the prior year.

Piotroski F-Score Neutral

4/9

Strata Critical Medical Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

-1.18x

For every $1 of reported earnings, Strata Critical Medical Inc generates $-1.18 in operating cash flow (-$48.9M OCF vs $41.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$197.1M

YoY+34.3%

5Y CAGR+53.1%

Strata Critical Medical Inc generated $197.1M in revenue in fiscal year 2025. This represents an increase of 34.3% from the prior year.

EBITDA

-$14.2M

YoY+14.5%

Strata Critical Medical Inc's EBITDA was -$14.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 14.5% from the prior year.

Net Income

$41.3M

YoY+251.4%

Strata Critical Medical Inc reported $41.3M in net income in fiscal year 2025. This represents an increase of 251.4% from the prior year.

EPS (Diluted)

$0.50

YoY+242.9%

Strata Critical Medical Inc earned $0.50 per diluted share (EPS) in fiscal year 2025. This represents an increase of 242.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$58.5M

YoY-75.3%

Strata Critical Medical Inc generated -$58.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 75.3% from the prior year.

Cash & Debt

$31.0M

YoY+68.5%

5Y CAGR+20.6%

Strata Critical Medical Inc held $31.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

20.9%

YoY+0.7pp

5Y CAGR+10.9pp

Strata Critical Medical Inc's gross margin was 20.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.7 percentage points from the prior year.

Operating Margin

-11.3%

YoY+4.0pp

5Y CAGR-8.4pp

Strata Critical Medical Inc's operating margin was -11.3% in fiscal year 2025, reflecting core business profitability. This is up 4.0 percentage points from the prior year.

Net Margin

21.0%

YoY+39.6pp

5Y CAGR+108.5pp

Strata Critical Medical Inc's net profit margin was 21.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 39.6 percentage points from the prior year.

Return on Equity

14.8%

YoY+27.1pp

5Y CAGR+200.0pp

Strata Critical Medical Inc's ROE was 14.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 27.1 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

YoY-100.0%

Strata Critical Medical Inc spent $0 on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 100.0% from the prior year.

Capital Expenditures

$9.6M

YoY-68.9%

5Y CAGR+91.0%

Strata Critical Medical Inc invested $9.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 68.9% from the prior year.

SRTAW Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$197.1M+34.3%	$146.8M-34.8%	$225.2M+54.1%	$146.1M+189.2%	$50.5M+115.6%	$23.4M
Cost of Revenue	$156.0M+33.1%	$117.2M-36.0%	$183.1M+47.8%	$123.8M+209.6%	$40.0M+89.5%	$21.1M
Gross Profit	$41.1M+39.0%	$29.6M-29.8%	$42.1M+89.1%	$22.3M+111.8%	$10.5M+352.0%	$2.3M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$60.9M+19.7%	$50.9M-46.6%	$95.2M+52.3%	$62.5M+107.4%	$30.1M+224.4%	$9.3M
Operating Income	-$22.4M+0.8%	-$22.5M+66.9%	-$68.1M-27.3%	-$53.5M-122.2%	-$24.1M-3451.0%	-$678K
Interest Expense	N/A	$7.2M-14.5%	$8.4M+145.8%	$3.4M+646.5%	$460K+131.2%	$199K
Income Tax	$0	$0+100.0%	-$1.5M-89.9%	-$772K+78.8%	-$3.6M-1830.9%	$210K
Net Income	$41.3M+251.4%	-$27.3M+51.3%	-$56.1M-105.7%	-$27.3M+31.9%	-$40.1M-95.2%	-$20.5M
EPS (Diluted)	$0.50+242.9%	$-0.35+53.9%	$-0.76-100.0%	$-0.38+59.1%	$-0.93-132.5%	$-0.40

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$22.7M-53.9%	$49.3M-30.4%	$70.8M+30.4%	$54.3M	N/A	$36.1M-46.9%	$67.9M+31.9%	$51.5M
Cost of Revenue	$22.9M-39.1%	$37.7M-29.0%	$53.1M+25.4%	$42.3M	N/A	$28.6M-44.7%	$51.6M+24.7%	$41.4M
Gross Profit	-$203K-101.7%	$11.6M-34.5%	$17.7M+48.1%	$12.0M	N/A	$7.5M-54.1%	$16.4M+61.3%	$10.1M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$7.1M-56.3%	$16.3M-19.1%	$20.1M+16.3%	$17.3M	N/A	$13.9M-44.8%	$25.1M+46.1%	$17.2M
Operating Income	-$4.2M+25.4%	-$5.6M-13.5%	-$5.0M+34.7%	-$7.6M	N/A	-$7.1M+41.6%	-$12.1M-23.1%	-$9.9M
Interest Expense	N/A	N/A	$1.2M-12.6%	$1.3M	N/A	$1.8M-1.3%	$1.8M-13.7%	$2.1M
Income Tax	-$4K	$0-100.0%	$21K+223.5%	-$17K	N/A	$0-100.0%	$52K+161.9%	-$84K
Net Income	-$8.8M-115.4%	$57.4M+1634.0%	-$3.7M-7.2%	-$3.5M	N/A	-$2.0M+82.7%	-$11.3M-167.5%	-$4.2M
EPS (Diluted)	N/A	$0.70+1500.0%	$-0.05-25.0%	$-0.04	N/A	$-0.03+80.0%	$-0.15-150.0%	$-0.06

SRTAW Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$325.5M+26.8%	$256.7M-13.0%	$294.9M-9.3%	$325.0M-5.3%	$343.4M+1838.4%	$17.7M
Current Assets	$126.2M-21.5%	$160.7M-22.1%	$206.3M-5.4%	$218.1M-30.6%	$314.4M+2086.8%	$14.4M
Cash & Equivalents	$31.0M+68.5%	$18.4M-34.1%	$27.9M-32.6%	$41.3M+494.6%	$7.0M-42.8%	$12.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$40.0M+101.6%	$19.8M-5.6%	$21.0M+93.1%	$10.9M+188.9%	$3.8M+244.8%	$1.1M
Goodwill	$88.2M+467.6%	$15.5M+16.6%	$13.3M-66.2%	$39.4M+197.2%	$13.3M	$0
Total Liabilities	$46.4M+33.6%	$34.7M-42.7%	$60.6M+20.0%	$50.5M-3.1%	$52.2M+686.2%	$6.6M
Current Liabilities	$19.8M-12.9%	$22.7M-36.0%	$35.5M+33.4%	$26.6M+179.2%	$9.5M+50.2%	$6.3M
Long-Term Debt	N/A	N/A	N/A	$0	N/A	N/A
Total Equity	$279.1M+25.7%	$221.9M-5.3%	$234.3M-14.6%	$274.5M-5.7%	$291.2M+2528.4%	$11.1M
Retained Earnings	-$145.6M+22.1%	-$186.9M-17.0%	-$159.8M-54.1%	-$103.7M-34.3%	-$77.2M-107.8%	-$37.1M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$325.5M-2.9%	$335.1M+29.9%	$257.9M+2.9%	$250.6M-2.4%	$256.7M-9.3%	$282.9M+0.9%	$280.3M-0.9%	$282.8M
Current Assets	$126.2M+3.0%	$122.5M-21.7%	$156.5M+2.7%	$152.3M-5.2%	$160.7M-6.4%	$171.8M-6.1%	$182.9M-5.7%	$194.0M
Cash & Equivalents	$31.0M+36.1%	$22.8M-61.3%	$58.8M+68.7%	$34.8M+89.5%	$18.4M-8.2%	$20.0M-23.9%	$26.3M-28.4%	$36.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$40.0M+6.4%	$37.5M+33.2%	$28.2M+27.3%	$22.1M+11.6%	$19.8M-19.0%	$24.5M-11.7%	$27.7M+17.7%	$23.6M
Goodwill	$88.2M+4.3%	$84.6M+91.2%	$44.3M+5.3%	$42.0M+170.5%	$15.5M-63.8%	$43.0M+8.5%	$39.6M-0.5%	$39.8M
Total Liabilities	$46.4M-10.9%	$52.1M+49.6%	$34.8M+13.0%	$30.8M-11.3%	$34.7M-29.7%	$49.4M-2.9%	$50.9M+10.3%	$46.2M
Current Liabilities	$19.8M-29.0%	$27.9M+5.9%	$26.3M+20.3%	$21.9M-3.7%	$22.7M-16.4%	$27.2M-10.3%	$30.3M+30.3%	$23.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$279.1M-1.4%	$283.0M+26.8%	$223.1M+1.5%	$219.7M-1.0%	$221.9M-5.0%	$233.5M+1.8%	$229.4M-3.1%	$236.6M
Retained Earnings	-$145.6M-6.5%	-$136.7M+29.6%	-$194.1M-2.0%	-$190.4M-1.9%	-$186.9M-5.5%	-$177.1M-1.1%	-$175.2M-6.8%	-$164.0M

SRTAW Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$48.9M-1841.8%	-$2.5M+92.2%	-$32.3M+12.9%	-$37.1M-137.8%	-$15.6M-1865.5%	-$794K
Capital Expenditures	$9.6M-68.9%	$30.9M+1363.3%	$2.1M+188.9%	$730K+145.8%	$297K-21.2%	$377K
Free Cash Flow	-$58.5M-75.3%	-$33.4M+3.1%	-$34.5M+9.0%	-$37.9M-137.9%	-$15.9M-1258.3%	-$1.2M
Investing Cash Flow	$69.8M+6965.2%	-$1.0M-105.9%	$17.1M-78.5%	$79.3M+124.7%	-$321.3M-96042.7%	$335K
Financing Cash Flow	-$8.9M-54.7%	-$5.8M-7477.6%	-$76K+93.0%	-$1.1M-100.3%	$332.3M+28057.5%	$1.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0-100.0%	$244K	$0	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$8.3M+77.7%	-$37.3M-1117.3%	-$3.1M-1145.5%	-$246K+86.0%	-$1.8M-127.6%	$6.4M-24.6%	$8.4M+154.2%	-$15.6M
Capital Expenditures	$1.8M-34.7%	$2.8M+23.1%	$2.3M-12.2%	$2.6M-42.8%	$4.6M-50.8%	$9.3M-42.4%	$16.2M+1880.8%	$816K
Free Cash Flow	-$10.2M+74.7%	-$40.1M-648.2%	-$5.4M-87.2%	-$2.9M+54.7%	-$6.3M-114.4%	-$3.0M+61.8%	-$7.7M+52.7%	-$16.4M
Investing Cash Flow	$18.3M+661.7%	$2.4M-91.6%	$28.7M+40.5%	$20.4M+413.3%	$4.0M+131.4%	-$12.6M+25.2%	-$16.9M-168.8%	$24.6M
Financing Cash Flow	-$1.7M+2.5%	-$1.8M-57.2%	-$1.1M+73.2%	-$4.2M-9.6%	-$3.9M-430.0%	-$731K+39.5%	-$1.2M-2337.0%	$54K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0	$0	N/A	N/A	$0	$0	N/A	N/A

SRTAW Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	20.9%+0.7pp	20.2%+1.4pp	18.7%+3.5pp	15.2%-5.6pp	20.8%+10.9pp	9.9%
Operating Margin	-11.3%+4.0pp	-15.3%+14.9pp	-30.3%+6.4pp	-36.6%+11.0pp	-47.7%-44.8pp	-2.9%
Net Margin	21.0%+39.6pp	-18.6%+6.3pp	-24.9%-6.2pp	-18.7%+60.6pp	-79.3%+8.3pp	-87.6%
Return on Equity	14.8%+27.1pp	-12.3%+11.6pp	-23.9%-14.0pp	-9.9%+3.8pp	-13.8%+171.5pp	-185.2%
Return on Assets	12.7%+23.3pp	-10.6%+8.4pp	-19.0%-10.6pp	-8.4%+3.3pp	-11.7%+104.2pp	-115.9%
Current Ratio	6.38-0.7	7.07+1.3	5.81-2.4	8.20-24.8	32.99+30.7	2.27
Debt-to-Equity	0.170.0	0.16-0.1	0.26+0.3	0.00-0.2	0.18-0.4	0.60
FCF Margin	-29.7%-6.9pp	-22.7%-7.4pp	-15.3%+10.6pp	-25.9%+5.6pp	-31.5%-26.5pp	-5.0%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	-0.9%-24.4pp	23.6%-1.5pp	25.1%+3.0pp	22.1%	N/A	20.8%-3.3pp	24.1%+4.4pp	19.7%
Operating Margin	-18.4%-7.0pp	-11.4%-4.4pp	-7.0%+7.0pp	-14.0%	N/A	-19.7%-1.8pp	-17.9%+1.3pp	-19.2%
Net Margin	-38.9%-155.3pp	116.5%+121.8pp	-5.3%+1.1pp	-6.4%	N/A	-5.4%+11.2pp	-16.7%-8.4pp	-8.2%
Return on Equity	-3.2%-23.5pp	20.3%+22.0pp	-1.7%-0.1pp	-1.6%	N/A	-0.8%+4.1pp	-4.9%-3.1pp	-1.8%
Return on Assets	-2.7%-19.9pp	17.1%+18.6pp	-1.5%-0.1pp	-1.4%	N/A	-0.7%+3.4pp	-4.0%-2.5pp	-1.5%
Current Ratio	6.38+2.0	4.39-1.6	5.95-1.0	6.96-0.1	7.07+0.8	6.32+0.3	6.04-2.3	8.35
Debt-to-Equity	0.17-0.0	0.18+0.0	0.16+0.0	0.14-0.0	0.16-0.1	0.21-0.0	0.22+0.0	0.20
FCF Margin	-44.7%+36.7pp	-81.4%-73.8pp	-7.6%-2.3pp	-5.3%	N/A	-8.2%+3.2pp	-11.4%+20.4pp	-31.8%

Frequently Asked Questions

What is Strata Critical Medical Inc's annual revenue?

Strata Critical Medical Inc (SRTAW) reported $197.1M in total revenue for fiscal year 2025. This represents a 34.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Strata Critical Medical Inc's revenue growing?

Strata Critical Medical Inc (SRTAW) revenue grew by 34.3% year-over-year, from $146.8M to $197.1M in fiscal year 2025.

Is Strata Critical Medical Inc profitable?

Yes, Strata Critical Medical Inc (SRTAW) reported a net income of $41.3M in fiscal year 2025, with a net profit margin of 21.0%.

What is Strata Critical Medical Inc's EBITDA?

Strata Critical Medical Inc (SRTAW) had EBITDA of -$14.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Strata Critical Medical Inc's gross margin?

Strata Critical Medical Inc (SRTAW) had a gross margin of 20.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Strata Critical Medical Inc's operating margin?

Strata Critical Medical Inc (SRTAW) had an operating margin of -11.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Strata Critical Medical Inc's net profit margin?

Strata Critical Medical Inc (SRTAW) had a net profit margin of 21.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Strata Critical Medical Inc's return on equity (ROE)?

Strata Critical Medical Inc (SRTAW) has a return on equity of 14.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Strata Critical Medical Inc's free cash flow?

Strata Critical Medical Inc (SRTAW) generated -$58.5M in free cash flow during fiscal year 2025. This represents a -75.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Strata Critical Medical Inc's operating cash flow?

Strata Critical Medical Inc (SRTAW) generated -$48.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Strata Critical Medical Inc's total assets?

Strata Critical Medical Inc (SRTAW) had $325.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Strata Critical Medical Inc's capital expenditures?

Strata Critical Medical Inc (SRTAW) invested $9.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

What is Strata Critical Medical Inc's current ratio?

Strata Critical Medical Inc (SRTAW) had a current ratio of 6.38 as of fiscal year 2025, which is generally considered healthy.

What is Strata Critical Medical Inc's debt-to-equity ratio?

Strata Critical Medical Inc (SRTAW) had a debt-to-equity ratio of 0.17 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Strata Critical Medical Inc's return on assets (ROA)?

Strata Critical Medical Inc (SRTAW) had a return on assets of 12.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Strata Critical Medical Inc's cash runway?

Based on fiscal year 2025 data, Strata Critical Medical Inc (SRTAW) had $31.0M in cash against an annual operating cash burn of $48.9M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Strata Critical Medical Inc's Piotroski F-Score?

Strata Critical Medical Inc (SRTAW) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Strata Critical Medical Inc's earnings high quality?

Strata Critical Medical Inc (SRTAW) has an earnings quality ratio of -1.18x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Strata Critical Medical Inc?

Strata Critical Medical Inc (SRTAW) scores 56 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.